Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.57 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016116 | 0.94 | AGTR2 (0.52) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL7019646 | 0.92 | AGTR2 (0.50) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Azilsartan SCHEMBL30604716 | 0.92 | AGTR2 (0.68) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Azilsartan SCHEMBL284893 | 0.92 | AGTR2 (0.68) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL7011956 | 0.91 | AGTR2 (0.57) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Azilsartan SCHEMBL7017834 | 0.91 | AGTR2 (0.67) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Azilsartan SCHEMBL7017842 | 0.91 | AGTR2 (0.67) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| Azilsartan SCHEMBL7017839 | 0.90 | AGTR2 (0.57) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL7017897 | 0.90 | AGTR2 (0.59) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL7011145 | 0.88 | PPARG (0.51) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673274-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AZILSARTAN MEDOXOMIL | JUBILANT GENERICS LTD (IN) | 2019-07-17 | — | — | EP | disclosed |
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | CHICAGO DISCOVERY SOLUTIONS, LLC | 2019-05-28 | — | — | US | disclosed |
| WO-2016147120-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE AZILSARTAN | SMILAX LABORATORIES LIMITED (IN) | 2016-09-22 | — | — | WO | disclosed |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| US-9233955-B2 | Process for the preparation of azilsartan medoxomil | JUBILANT LIFE SCIENCES, LTD. (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233955-B2 | Process for the preparation of azilsartan medoxomil | JUBILANT LIFE SCIENCES, LTD. (IN) | 2016-01-12 | — | — | US | disclosed |
| WO-2015054120-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2012157977-A9 | MANUFACTURING METHOD OF HETEROCYCLIC COMPOUND | HANMI FINE CHEMICAL CO., LTD. (KR) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012157980-A9 | MANUFACTURING METHOD OF AZILSARTAN | HANMI FINE CHEMICAL CO., LTD. (KR) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012157977-A2 | MANUFACTURING METHOD OF HETEROCYCLIC COMPOUND | HANMI FINE CHEMICAL CO., LTD. (KR) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012157980-A2 | MANUFACTURING METHOD OF AZILSARTAN | HANMI FINE CHEMICAL CO., LTD. (KR) | 2012-11-22 | — | — | WO | disclosed |
| EP-0520423-B1 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6100252-A | SPECIFIED COMPOUNDS INCLUDING METHYL 2-BUTYL-1-((2'-(2-OXO-3H-1,2,3,5-OXATHIADIAZOL-4-YL)BIPHENYL) METHYL)-BENZIMIDAZOLE-7-CARBOXYLATE; USE TO TREAT CIRCULATORY DISEASES SUCH AS HYPERTENSIVE DISEASES AND HEART DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-5639773-A | TREATING GLAUCOMA | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| US-5583141-A | ADMINISTERING AS THERAPEUTIC AGENTS OF CIRCULATORY DISEASES; AZILSARTAN; ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| WO-1995001176-A1 | USE OF AN ANGIOTENSIN II ANTAGONIST AS AN OCULAR HYPOTENSIVE AGENT | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-12 | — | — | WO | disclosed |
| EP-0631780-A1 | Use of an angiotensin II antagonist as an ocular hypotensive agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5354766-A | 2-Ethoxy-1-((2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl)methyl)benzimidazole-7-carboxylic acid; hypotensive agents; CNS activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| US-5243054-A | Hypotensive agents, cardiovascular disorders or nervous system disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0520423-A2 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | RUVBL2, RUVBL1, CYP2W1 | AGTR2 265/4885CYP3A4 77/4885ADORA3 1841/4885 |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | RUVBL2, RUVBL1, CYP2W1 | AGTR2 265/4885CYP3A4 77/4885ADORA3 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.